Profile data is unavailable for this security.
About the company
Amplia Therapeutics Limited is an Australia-based clinical-stage, drug development company. The Company is focused on developing proprietary, orally available, small molecule Focal Adhesion Kinase (FAK) inhibitors as candidate drugs for the treatment of cancer and various fibrotic diseases. Its pipeline includes narmafotinib (AMP945) and AMP886. Its lead drug candidate, narmafotinib, is a selective and potent inhibitor of FAK and is currently in a phase 2 clinical trial for pancreatic cancer, in clinical development for ovarian cancer, and advanced preclinical development for idiopathic pulmonary fibrosis (IPF). The Company’s second pipeline drug, AMP886, inhibits FAK and inhibits two key disease drug targets (VEGFR3 and FLT3). This drug is being evaluated in preclinical models of cancer. Its cancer Program is directed at using its FAK inhibitors to block FAK activity in the cancer cells and the surrounding tissue.
- Revenue in AUD (TTM)5.01m
- Net income in AUD-7.93m
- Incorporated2013
- Employees1.00
- LocationAmplia Therapeutics LtdLevel 17, 350 Queen StreetMELBOURNE 3000AustraliaAUS
- Phone+61 39123-1140
- Websitehttps://www.ampliatx.com/site/content/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Argenica Therapeutics Ltd | 512.75k | -7.17m | 36.61m | -- | -- | 5.06 | -- | 71.40 | -0.0559 | -0.0559 | 0.004 | 0.0564 | 0.0374 | -- | 1.29 | -- | -52.31 | -47.11 | -67.68 | -55.90 | -- | -- | -1,398.41 | -2,938.71 | -- | -20,767.20 | 0.00 | -- | 166.93 | 359.61 | -30.86 | -- | -- | -- |
| Algorae Pharmaceuticals Ltd | 141.05k | -802.96k | 37.15m | -- | -- | 16.66 | -- | 263.41 | -0.0005 | -0.0005 | 0.00008 | 0.0013 | 0.0505 | -- | 3.38 | -- | -28.72 | -51.95 | -30.63 | -56.76 | -- | -- | -569.27 | -1,452.78 | -- | -- | 0.00 | -- | 12.66 | -23.93 | 61.68 | -- | -- | -- |
| Anteotech Ltd | 1.03m | -6.76m | 38.65m | 40.00 | -- | 11.16 | -- | 37.61 | -0.0025 | -0.0025 | 0.0004 | 0.0012 | 0.1299 | -- | 6.90 | -- | -85.41 | -76.84 | -106.22 | -87.65 | -- | -- | -657.69 | -1,253.69 | -- | -- | 0.3835 | -- | 99.60 | 27.97 | 23.89 | -- | -4.02 | -- |
| Neuroscientific Biopharmaceuticals Ltd | 166.08k | -1.85m | 43.23m | -- | -- | 2.57 | -- | 260.33 | -0.0126 | -0.0126 | 0.0011 | 0.0506 | 0.0148 | -- | 2.17 | -- | -16.48 | -37.13 | -16.65 | -40.11 | -- | -- | -1,111.22 | -185.57 | -- | -746.17 | 0.00 | -- | -93.05 | 16.84 | -669.23 | -- | -- | -- |
| Emyria Ltd | 1.39m | -3.14m | 44.36m | -- | -- | 6.34 | -- | 31.80 | -0.0069 | -0.0069 | 0.0031 | 0.0087 | 0.2316 | -- | 40.72 | -- | -52.19 | -82.51 | -69.83 | -106.69 | 1.76 | -17.98 | -225.33 | -355.61 | -- | -22.44 | 0.1037 | -- | -36.68 | 6.60 | 72.57 | -- | -41.45 | -- |
| Entropy Neurodynamics Ltd | 1.59m | -5.33m | 48.49m | -- | -- | 7.48 | -- | 30.54 | -0.0043 | -0.0043 | 0.0012 | 0.0041 | 0.2249 | -- | 0.763 | -- | -75.55 | -- | -92.06 | -- | -- | -- | -335.91 | -- | -- | -100.79 | 0.00 | -- | -- | -10.25 | -- | -- | -26.73 | -- |
| Syntara Ltd | 7.48m | -12.26m | 55.52m | 107.00 | -- | 3.45 | -- | 7.42 | -0.0084 | -0.0054 | 0.0051 | 0.0099 | 0.4701 | -- | 2.53 | -- | -77.03 | -36.39 | -116.54 | -50.26 | -- | -- | -163.86 | -78.37 | -- | -953.38 | 0.0052 | -- | 37.80 | -9.83 | 10.31 | -- | -- | -- |
| Amplia Therapeutics Ltd | 5.01m | -7.93m | 61.57m | 1.00 | -- | 1.43 | -- | 12.30 | -0.0204 | -0.0204 | 0.0128 | 0.0837 | 0.1705 | -- | 1.28 | -- | -27.01 | -27.37 | -28.31 | -30.38 | -- | -- | -158.46 | -180.53 | -- | -- | 0.0088 | -- | -15.01 | 156.11 | -45.93 | -- | -- | -- |
| Clever Culture Systems Ltd | 6.52m | 1.68m | 65.19m | 17.00 | 38.46 | 9.39 | 34.15 | 10.00 | 0.0008 | 0.0008 | 0.0031 | 0.0032 | 0.6975 | 0.9829 | 6.37 | -- | 18.01 | -36.73 | 22.73 | -42.00 | 77.05 | -- | 25.82 | -281.21 | 1.63 | -- | 0.2653 | -- | 397.86 | 30.08 | 145.03 | -- | 24.71 | -- |
| Rhythm Biosciences Ltd | 3.33m | -3.83m | 73.59m | -- | -- | 98.99 | -- | 22.13 | -0.0134 | -0.0134 | 0.0124 | 0.0023 | 1.53 | 98.79 | 67.11 | -- | -176.04 | -146.24 | -469.96 | -197.40 | -10.44 | 22.48 | -115.14 | -287.42 | 0.8046 | -53.89 | 0.6266 | -- | 90.87 | 135.14 | 44.15 | -- | -12.61 | -- |
| Prescient Therapeutics Ltd | 225.61k | -7.32m | 73.61m | 3.00 | -- | 4.95 | -- | 326.25 | -0.0091 | -0.0091 | 0.0003 | 0.0141 | 0.0129 | -- | 0.9582 | -- | -41.90 | -31.70 | -49.69 | -34.33 | -- | -- | -3,245.66 | -2,146.75 | -- | -590.48 | 0.00 | -- | -67.19 | 26.24 | 11.11 | -- | -- | -- |
| Proteomics International LaboratoriesLtd | 3.31m | -8.11m | 75.16m | -- | -- | 5.65 | -- | 22.69 | -0.0605 | -0.0605 | 0.0247 | 0.0805 | 0.2582 | -- | 12.02 | -- | -63.57 | -63.62 | -68.88 | -71.91 | -- | -- | -246.18 | -222.10 | -- | -- | 0.021 | -- | 1.34 | 15.81 | -27.27 | -- | -54.88 | -- |
| Imugene Ltd | 0.00 | -69.02m | 83.59m | 0.00 | -- | 1.27 | -- | -- | -0.3161 | -0.3161 | 0.00 | 0.205 | 0.00 | -- | -- | -- | -58.75 | -48.72 | -75.21 | -53.73 | -- | -- | -- | -- | -- | -- | 0.1913 | -- | -- | -- | 53.89 | -- | 38.40 | -- |
| Alterity Therapeutics Ltd | 446.29k | -12.15m | 87.00m | 9.00 | -- | 1.72 | -- | 194.95 | -0.002 | -0.002 | 0.00007 | 0.0047 | 0.0137 | -- | 5,578.63 | 49,587.78 | -37.23 | -49.00 | -43.12 | -57.35 | -- | -- | -2,721.96 | -9,708.51 | -- | -211.82 | 0.0037 | -- | 66.27 | 91.97 | 36.48 | -- | -- | -- |
| Cynata Therapeutics Ltd | 227.70k | -9.39m | 91.42m | 0.00 | -- | 14.54 | -- | 401.49 | -0.0453 | -0.0453 | 0.0011 | 0.0265 | 0.0292 | -- | 2.16 | -- | -120.50 | -48.36 | -142.29 | -53.09 | -- | -- | -4,124.10 | -576.20 | -- | -1,268.00 | 0.00 | -- | -45.49 | 28.12 | 3.63 | -- | -- | -- |
Data as of Feb 11 2026. Currency figures normalised to Amplia Therapeutics Ltd's reporting currency: Australian Dollar AUD
18.94%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Platinum Investment Management Ltd.as of 21 Jan 2026 | 41.68m | 8.12% |
| Acorn Capital Ltd.as of 29 Jul 2025 | 36.14m | 7.05% |
| Pengana Capital Ltd.as of 31 Oct 2025 | 18.81m | 3.67% |
| DFA Australia Ltd.as of 31 Dec 2025 | 535.62k | 0.10% |
More ▼
Data from 30 Sep 2025 - 12 Jan 2026Source: FactSet Research Systems Inc.
